e-PKGene: A knowledge-based research tool for analysing the impact of genetics on drug exposure

Abstracte-PKGene (http://www.pharmacogeneticsinfo.org) is a manually curated knowledge product developed in the Department of Pharmaceutics at the University of Washington, USA. The tool integrates information from the literature, public repositories, reference textbooks, product prescribing labels and clinical review sections of new drug approval packages. The database's easy-to-use web portal offers tools for visualisation, reporting and filtering of information. The database helps scientists to mine pharmacokinetic and pharmacodynamic information for drug-metabolising enzymes and transporters, and provides access to available quantitative information on drug exposure contained in the literature. It allows in-depth analysis of the impact of genetic variants of enzymes and transporters on pharmacokinetic responses to drugs and metabolites. This review gives a brief description of the database organisation, its search functionalities and examples of use.

[1]  E. Hatano,et al.  Impact of regulatory polymorphisms in organic anion transporter genes in the human liver , 2009, Pharmacogenetics and genomics.

[2]  A. Bhathena,et al.  Pharmacogenetics: improving drug and dose selection. , 2008, Current opinion in pharmacology.

[3]  M. Khoury,et al.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? , 2007, Genetics in Medicine.

[4]  Janet Woodcock,et al.  Pharmacogenetics--tailoring treatment for the outliers. , 2009, The New England journal of medicine.

[5]  Guilherme Del Fiol,et al.  Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice , 2012, Journal of personalized medicine.

[6]  Juan P. Casas,et al.  Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies , 2009, PloS one.

[7]  Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels , 2009 .

[8]  David A. Katz,et al.  Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy , 2008, Nature Reviews Drug Discovery.

[9]  A. Daly,et al.  Genome-wide association studies in pharmacogenomics , 2010, Nature Reviews Genetics.

[10]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[11]  M. Khoury Dealing With the Evidence Dilemma in Genomics and Personalized Medicine , 2010, Clinical pharmacology and therapeutics.

[12]  P. Deverka Pharmacogenomics, Evidence, and the Role of Payers , 2009, Public Health Genomics.

[13]  J. Woodcock,et al.  Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective , 2004, Nature Reviews Drug Discovery.